ILUMETRI 100 mg, solution for injection in a pre-filled syringe syringe, 1 ml
Active ingredients: Tildrakizumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 1 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ILUMETRI 100 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue préremplie en verre de 1 ml
- Marketing authorisation holder
- ALMIRALL (ESPAGNE)
- Reimbursement according to BDPM
- 65%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Psoriasis en plaque (maladie immunitaire se manifestant par l'apparition de plaques de peau morte) dans sa forme grave. ; JOURNAL OFFICIEL ; 10/10/20
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 Oct 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69596271CIP73017205CIP133400930172056Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TILDRAKIZUMABsolution | 100 mg · une seringue préremplie de 1 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.